{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T05:56:22Z","timestamp":1718949382646},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":1416,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nucl Med"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:p>Radioimmunotherapy (RIT) has been available for some time to treat patients with non-Hodgkin's lymphoma, but its use in Hodgkin's lymphoma has been less available, partly because of the need to find an appropriate antibody. A new radioiodinated chimeric antibody directed against the CD25 epitope (131I basiliximab) seems promising, but assessment of response has been difficult. 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) has become a standard method by which the response of Hodgkin's disease to chemotherapy is both predicted and assessed with well-understood criteria of response. The aim of this study is to determine18F-FDG-PET can be used to assess response to RIT. Pre- and post-treatment 18F-FDG-PET imaging was performed in a series of 13 patients with advanced Hodgkin's disease who had failed conventional therapy and had been enrolled on a compassionate use program for treatment with 131I basiliximab. The 131I basiliximab was given at an activity of 1200MBq\/m2 with one patient receiving 2 cycles and the rest a single cycle. The 18F-FDG-PET studies were compared using the \u201cDeauville\u201d criteria and by comparing the maximum standardized uptake value (SUVmax) of target tumors before and 4 and 8 weeks after treatment. All patients survived long enough for their initial 18F-FDG-PET-computed tomography scan at 4 weeks after their 131I basiliximab therapy. One out of ten patients with \u201cDeauville\u201d Grade 4 or 5 response died during the 6-month follow-up period. Two out of three patients with a \u201cDeauville\u201d Grade 2 or 3 response died in the follow-up period. The mean SUVmax pretreatment was 11.9 (\u00b14.7); at 4-week posttreatment, the mean SUVmax was significantly lower at 6.5 (\u00b15.8) (P = 0.02). At 8 weeks, the mean SUVmax was 8.8 (\u00b17.0), which was not significantly different from the pretreatment level. 18F-FDG-PET imaging is able to predict the short-term response to treatment of Hodgkin's disease by RIT, and an initial poor response appears to predict poor outcome. Early changes in 18F-FDG-PET uptake did not predict sustained response and by 8 weeks all but one patient had recurrent disease.<\/jats:p>","DOI":"10.4103\/wjnm.wjnm_50_17","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T09:01:23Z","timestamp":1529571683000},"page":"171-177","source":"Crossref","is-referenced-by-count":2,"title":["Use of 18F FDG PET and the short temporal response of Hodgkin's disease to RIT"],"prefix":"10.1055","volume":"17","author":[{"given":"Ewa","family":"Nowosinska","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, St Bartholomew's Hospital, London EC1A 7BE, England"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Royal Free Hospital, London NW3 2QG, England"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Buscombe","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Addenbrookes Hospital, Cambridge CB2 0QQ, England"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"key-10.4103\/1450-1147.234891-1","first-page":"174","volume-title":"Mantle treatment of Hodgkin's disease.Preliminary report of side effects and early results","author":"Landberg","year":"1971","journal-title":"Acta Radiol Ther Phys Biol"},{"key":"key-10.4103\/1450-1147.234891-2","first-page":"833","volume-title":"Results of involved field and extended field radiotherapy in patients with pathologic state I and II Hodgkin's disease","author":"Miller","year":"1976","journal-title":"Am J Roentgenol"},{"key":"key-10.4103\/1450-1147.234891-3","first-page":"1693","volume-title":"Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease","author":"Ng","year":"2006","journal-title":"Ann Oncol"},{"key":"key-10.4103\/1450-1147.234891-4","first-page":"1713","volume-title":"Split-course radiotherapy of Hodgkin's disease: Local tumor control and normal tissue reactions","author":"Johnson","year":"1976","journal-title":"Cancer"},{"key":"key-10.4103\/1450-1147.234891-5","first-page":"1235","volume-title":"Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation","author":"Coleman","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key-10.4103\/1450-1147.234891-6","doi-asserted-by":"crossref","unstructured":"Hoskin PJ, D\u00edez P, Williams M, Lucraft H, Bayne M. Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol (R Coll Radiol) 2013;31:308-13. [In press].","DOI":"10.1016\/j.clon.2012.07.011"},{"key":"key-10.4103\/1450-1147.234891-7","first-page":"609","volume-title":"Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: Patterns of failure, late toxicity and second malignancies","author":"Vlachaki","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key-10.4103\/1450-1147.234891-8","first-page":"25","volume-title":"Breast cancer after treatment of Hodgkin's disease","author":"Hancock","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/1450-1147.234891-9","first-page":"2745","volume-title":"Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and wales: A National cohort study","author":"Swerdlow","year":"2012","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1450-1147.234891-10","first-page":"589","volume-title":"A systematic overview of radiation therapy effects in Hodgkin's lymphoma","author":"Gustavsson","year":"2003","journal-title":"Acta Oncol"},{"key":"key-10.4103\/1450-1147.234891-11","first-page":"391","volume-title":"Screening Hodgkin lymphoma survivors for radiotherapy induced cardiovascular disease","author":"van","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"key-10.4103\/1450-1147.234891-12","first-page":"2934","volume-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","author":"Press","year":"2000","journal-title":"Blood"},{"key":"key-10.4103\/1450-1147.234891-13","first-page":"3918","volume-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1450-1147.234891-14","first-page":"1316","volume-title":"Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed\/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas","author":"Vose","year":"2000","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1450-1147.234891-15","first-page":"2453","volume-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1450-1147.234891-16","first-page":"5156","volume-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1450-1147.234891-17","doi-asserted-by":"crossref","unstructured":"Scholz CW, Pinto A, Linkesch W, Lind\u00e9n O, Viardot A, Keller U, et al. 90Yttrium-Ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 2013;31:308-13. [In press].","DOI":"10.1200\/JCO.2011.41.1553"},{"key":"key-10.4103\/1450-1147.234891-18","first-page":"196","volume-title":"Radioimmunotherapy for B-cell non-Hodgkin lymphomas","author":"Tomblyn","year":"2012","journal-title":"Cancer Control"},{"key":"key-10.4103\/1450-1147.234891-19","first-page":"2394","volume-title":"Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment","author":"Herpst","year":"1995","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1450-1147.234891-20","first-page":"3324s","volume-title":"Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease","author":"Vriesendorp","year":"1999","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1450-1147.234891-21","first-page":"7701","volume-title":"A phase I clinical trial of CHT-25 a 131I-labeled chimeric anti-CD25 antibody showing efficacy in patients with refractory lymphoma","author":"Dancey","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1450-1147.234891-22","first-page":"1225","volume-title":"Prognostic value of PET using 18F-FDG in Hodgkin's disease for post treatment evaluation.J Nucl Med","author":"Guay","year":"2003","journal-title":""},{"key":"key-10.4103\/1450-1147.234891-23","first-page":"87","volume-title":"The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: Preliminary results of a prospective study","author":"Paolini","year":"2007","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"key-10.4103\/1450-1147.234891-24","first-page":"1906","volume-title":"Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: A systematic review","author":"Terasawa","year":"2009","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1450-1147.234891-25","first-page":"4913","volume-title":"Interim FDG-PET in Hodgkin lymphoma: A compass for a safe navigation in clinical trials?","author":"Gallamini","year":"2012","journal-title":"Blood"},{"key":"key-10.4103\/1450-1147.234891-26","first-page":"292","volume-title":"High-dose chemo\/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission","author":"Nademanee","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"key":"key-10.4103\/1450-1147.234891-27","first-page":"244","volume-title":"Radioiodination for therapy","author":"Adam","year":"1989","journal-title":"Ann Clin Biochem"},{"key":"key-10.4103\/1450-1147.234891-28","first-page":"1824","volume-title":"Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma","author":"Barrington","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"key-10.4103\/1450-1147.234891-29","first-page":"15","volume-title":"The molecular pathogenesis of Hodgkin lymphoma","author":"Farrell","year":"2011","journal-title":"Histopathology"},{"key":"key-10.4103\/1450-1147.234891-30","first-page":"313","volume-title":"Early intensive therapy with autologous stem cell transplantation in high-risk Hodgkin's disease: Long-term follow-up in 35 cases","author":"Moreau","year":"1998","journal-title":"Leuk Lymphoma"}],"container-title":["World Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.4103\/wjnm.WJNM_50_17.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T22:41:09Z","timestamp":1652827269000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.4103\/wjnm.WJNM_50_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":30,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2022,5,17]]},"published-print":{"date-parts":[[2018,7]]}},"URL":"https:\/\/doi.org\/10.4103\/wjnm.wjnm_50_17","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1450-1147","1607-3312"],"issn-type":[{"value":"1450-1147","type":"print"},{"value":"1607-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}